MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

MET as a target for treatment of chest tumors

Lung Cancer. 2008 Jul 29. [Epub ahead of print] [Link]

Cipriani NA, Abidoye OO, Vokes E, Salgia R.

Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, United States; Department of Pathology, and University of Chicago Cancer Research Center, University of Chicago Medical Center, Chicago, IL 60637, United States.

Abstract

The receptor tyrosine kinase MET has been studied of a large variety of human cancers, including lung and mesothelioma. The MET receptor and its ligand HGF (hepatocyte growth factor) play important roles in cell growth, survival and migration, and dysregulation of the HGF-MET pathway leads to oncogenic changes including tumor proliferation, angiogenesis and metastasis. In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms. New drugs targeted against MET and HGF are currently being investigated in vitro and in vivo, with promising results. These drugs function at a variety of steps within the HGF-MET pathway, including MET expression at the RNA or protein level, the ligand-receptor interaction, and tyrosine kinase function. This paper will review the structure, function, mechanisms of tumorigenesis, and potential for therapeutic inhibition of the MET receptor in lung cancer and mesothelioma.

Both comments and trackbacks are currently closed.